Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin continuous infusion target attainment in CABG prophylaxis
2017-000934-77Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Apr 2018
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of cefazolin and dalbavancin in surgical site infection (SSI), bacterial disease and Staphylococcus aureus infection (3 arms), sponsored by Medical University of Vienna. Primary endpoints: Target attainment in subcutaneous tissue, Beneficial effect of advanced preoperative antibiotic regimen and 1 more. Started Apr 2018; status: completed.
02
Drugs
cefazolindalbavancin
03
Conditions
surgical site infection (SSI)bacterial diseaseStaphylococcus aureus infection
Beyond the preview
Go deeper on 2017-000934-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000934-77.